Document:

Collaboration Agreement

 Exhibit 10.8 
 Collaboration Agreement on 
 the Establishment of Innovative Drug United Lab by Tsinghua

 University (Department of Chemistry) and Jiangsu Simcere 
 Pharmaceutical R&D Co., Ltd. 
 Party A: Jiangsu Simcere Pharmaceutical R&D Co.,
Ltd. 
 Party B: Tsinghua University (Department of Chemistry) 
  

	1.	Collaboration Philosophy 

  

	1.1	Based on the principle of friendly collaboration, mutual benefits, exploitation of complementary advantages, co-development and the Win-Win, Jiangsu Simcere Pharmaceutical R&D
Co., Ltd, a subsidiary company of Simcere Investments Group Ltd, and Tsinghua University (Department of Chemistry) hereby agree to establish a innovative drug united lab (the “Lab”)to combine Tsinghua University (Department of
Chemistry)’s solid foundation about the innovative drug research and talents and the outstanding academic predominance with Simcere Investments Group Ltd’s financial and technical advantages. 

  

	1.2	Purpose of the Establishment of the Lab: Parties hereto cooperate with each other to carry out the research and development of innovative drug with independent intellectual
property, including without limitation to designing and synthesizing the NCEs for the treatment of cancer, viral diseases and neurological diseases. It is estimated that several lead compounds will be obtained within the term of the collaboration.
Series of biological tests will be carried out to determine the activity of these lead compounds and their derivatives. Parties hereto expect to apply, with the cooperation achievements, for the key technological research grant and the applied
technology grant in Pharmaceutical industry of the local and national government. 

  

	2.	Organization 

  

	2.1	The Lab is an unincorporated body which is located in Tsinghua University and affiliated to Department of Chemistry of Tsinghua University. 

  

	2.2	The Lab is operated by the lab director which is under the leadership of the management committee. The management committee consists of six members, three from Party A and the other
three from Party B. The director of the committee shall be appointed by Party B. 

  

	2.3	The management committee shall be responsible for the examination and approval of projects, financial issues and the decision-making about the overall work of the Lab and key
projects. 

  

	2.4	The management committee shall have one director and one associate director to be responsible for the Lab’s daily management and the directing relevant researches. The
Lab’s director shall be appointed by Party B while the associate director shall be appointed Party A. 

  

	3.	Responsibilities 

  

	 	•	 	 Party A 

  

	3.1	During the term of this Agreement, Party A should provide at least RMB 6,000,000.00 to the Lab. The fund provided in the first year shall not be less than RMB 2,000,000.00 including
the “initiation expenses” of RMB 500,000.00.The “daily operation expenses” for each year shall be RMB 400,000.00. The total research and development expenses shall be RMB 4,300,000.00. 

 Payment mode is listed as below: 
  

			
	3.1.1	  	Total RMB 900, 000.00 for the initiation expenses and the daily operation expenses of the first year shall be paid within two weeks as from the date this Agreement go into
effect.
		
	3.1.2	  	The daily operation expenses for the second year and third year shall be paid before 15th Jan, 2007 and 15th Jan, 2008 respectively.
		
	3.1.3	  	The research and development expenses shall be paid after innovative drug research project or technique breakthrough project is approved by the management committee in accordance with relevant
provisions of specific project agreement.
		
	3.1.4	  	Party A promises that the fund provided accumulatively in the first year, 2006, shall not be less than RMB 2,000,000.00.

  

	3.2	During the three-year term of this Agreement, the project application and relevant budget application shall be proposed by the lab director and approved by the management committee,
and the research and development expenses shall be paid by Party A in accordance with relevant provisions of specific project agreement. 

  

	 	•	 	 Party B 

  

	3.3	Party B shall supply the human resources, technologies and the site for the Lab. 

  

	3.4	Party B shall complete the research project approved by management committee, and shall assist Party A to commercialize the research project. 

  

	4	Ownership of Intellectual Property Right 

  

	4.1	The ownership of intellectual property rights owned by parties hereto before the establishment of the Lab shall remain unchanged. 

  

	4.2	The obligations, rights and benefits between parties hereto shall be decided in accordance with specific technological agreement signed by parties hereto after the establishment of
the Lab. 

  

	5	Breach Liabilities 

  

	5.1	Party A shall undertake default liabilities in case Article 3.1 and 3.2 of this Agreement are violated. 

  

	5.2	Party B shall undertake default liabilities in case Article 3.3 and 3.4 of this Agreement are violated. 

 Party A or Party B shall be entitled to request the default party to undertake default liabilities, and shall be entitled to rescind this Agreement with a writing notice sent to the default party. In case the default
party does not give its answer within 2 months as from the date it receive said written notice, this agreement shall be deemed as having been rescinded and the Lab shall also be dissolved at the same time. 
  

  

	6	Arbitration 

 Any dispute arising between parties
hereto shall be first settled through friendly negotiation. In case said dispute cannot be settled through negotiation, parties here to may apply their respective superior entity to carry out mediation. In case parties hereto cannot reach an
agreement through mediation, relevant dispute shall be submitted to Beijing Arbitration Commission for arbitration. This arbitration award shall be final, and bind parties hereto. 
  

	7	Restriction and Non-disclosure 

  

	7.1	Parties hereto shall not register any independent corporation or participate in any commercial activities beyond the stipulated scope in the name of the Innovative Drug United Lab
of Tsinghua University (Department of Chemistry) and Jiangsu Simcere Pharmaceutical R&D Co., Ltd. Parties hereto shall safeguard both parties’ reputation and interests. 

  

	7.2	Either party shall keep any and all technology information and materials provided by the other party confidential. This clause shall survive whatever this agreement is amended,
rescinded or terminated. 

  

	8	Term 

 The term of this Agreement shall be three
years. This Agreement shall go into effect after being signed by both parties. Parties here to may negotiate on following matters 3 months before this Agreement expires: 
  

	8.1	in case the renewal requirements is satisfied, parties hereto may apply to their respective superior leader for the approval of the renewal of this Agreement;

  

	8.2	in case the renewal requirements is not satisfied, parties hereto shall sign a separate termination agreement and dissolve the Lab. In case either party doesn’t sign the
termination agreement within two months after the this Agreement expires, the other party shall be entitled to send a written notice to said party. In case said party does not answer said written notice within 1 month as from the date of receipt,
this Agreement shall be deemed as having been rescinded and the Lab shall be dissolved. 

  

	8.3	In case the Lab cannot be operated any longer due to force majeure, this agreement may be terminated earlier if parties hereto agree. 

  

	9	Miscellaneous 

  

	9.1	Neither party is allowed to participate in any activities in the name of the Lab after this Agreement is terminated. Parties hereto shall safeguard the reputation and interests of
both parties. This clause shall survive whatever this agreement is amended, rescinded or terminated. 

  

	9.2	Any amendments, supplements or alterations to this Agreement shall not go into effect unless made in the writing and signed by both parties (Party B shall get approval from
competent authorities of Tsinghua University). Said documents shall have the same effect as that of this Agreement. 

  

	9.3	This Agreement shall be in 10 copies. Party A shall keep 4 copies and Party B shall keep 6 copies. 

 Jiangsu Simcere Pharmaceutical R&D Co Ltd 
 (seal) 
 Representative: (signature) 
 Correspondent: (signature) 
 Tsinghua University (Department of Chemistry) 
 (seal) 
 Representative: (signature) 
 Correspondent: (signature)Technical Development Agreement

 Exhibit 10.9 
 Technical Development Agreement 
 Project Name: Preclinical Pharmacodynamic Research on Endostar’s New
Indications 
 Party A: Jiangsu Simcere Pharmaceutical R&D Co., Ltd. 
 Party B: Shanghai Institute of Materia Medica, Chinese Academy of Sciences 
 Contract No.: 06310434000

 Date: November 2, 2006 
 Place of Signature:
Shanghai 
 Parties hereto hereby sign this Agreement to deal with relevant matters concerning the preclinical pharmacodynamic research on
Endostar’s new indication: 
 1. Technologies and Relevant Requirements 
 1.1 Party B shall complete the preclinical pharmacodynamic research on Endostar’s new indications in accordance with declaration requirements of Class I New Drug, and shall provide related data generated from the
research to Party A, and shall assure that these data may be directly used to carry out IND applications for Endostar’s new indication, such as colon carcinoma, liver cancer, gastric cancer and melanoma, to SFDA. 
 The specific research shall include: 
 1.1.1 Anti-tumour experiments in vivo:

 Endostar’s experimental therapy of 8 categories of human cancer xenograft models, including human colon carcinoma HCT-116 model, human gastric cancer
HT-29 model, human liver cancer Bel-7402 model, human liver cancer SMMC-7721 model, human gastric cancer SGC-7901 model, human gastric cancer MKN-28 model, human melanoma A375 model and human melanoma A2058 model, and each model shall go through 2
experiments. Party B shall complete relevant experiments one by one according to tissue sources of tumors and provide experimental data and reports complying with relevant requirements of SFDA to Party A. 
 1.1.2 The design and finalization of relevant experimental schemes concerning above-mentioned experiments. 
 1.2 Party B shall complete above-mentioned research within fourteen months as from the date when parties hereto sign this Agreement
(from November 10th, 2006 to January 1st, 2008), and shall provide all related information, including experimental reports, data, to Party A. 

 1.3 Besides above-mentioned experiments, if the therapeutic effect of Endostar on these tumor models is proved, Party B
shall also be responsible for following issues: 
 1.3.1 Party B shall prepare IND application dossiers on the preclinical pharmacodynamic research on
Endostar’s new indications basing on relevant experimental data. 
 1.3.2 Party B shall be responsible to answer questions about the preclinical
pharmacodynamic research on Endostar’s new indications when SFDA reviews relevant dossiers. 
 1.3.3 If necessary, Party B shall carry out additional
efficacy experiments required by SFDA. 
 1.3.4 Preclinical pharmacodynamic research report on Endostar’s new indications shall be approved by SFDA.

 1.4 Party A shall provide enough and qualified Endostar samples accompanying relevant batch number and analysis report, and shall pay research and
development fund in accordance with Article 3 of this Agreement so as to ensure that the research may smoothly proceed. 
 1.5 Party A shall provide existing
research data to Party B and assist B in the research. 
 1.6 Party B shall purchase Human melanoma A2058 cell line with fund provided by Party A.

 2. Technological Indexes and Parameters: 
 Party B
shall ensure the authenticity and scientificity of the experiment process, results and all information generated from these experiments, and shall provide a detail experimental report and a copy of experiment information. 
 Experiment process shall be carried out in accordance with state requirements on new drug development, and relevant experimental reports shall comply with state
requirements on new drug declaration, and ensure that relevant information and data may be used by Party A to carry out IND applications for Endostar’s new indications. 
 3. Research and Development Schedule 
 Party B shall complete
above-mentioned research within fourteen months as from the date this Agreement is signed (from November 10th,
2006 to January 10th, 2008), and shall provide all related information to Party A, including without limitation
to experimental reports and data 

 4. Research and Development Fund, Remuneration and Payment Mode 
 4.1 Research and development fund means the R&D cost for this project. Remuneration means the consideration for the development of this project and the subsidies for
researchers. 
 The total research and development fund and remuneration shall be RMB 600,000.00. 
 4.2 The research and development fund and remuneration shall be paid in 2 installments. The first installment shall be RMB 400,000.00 paid within one week as from the
date this Agreement is signed. The second installment shall be RMB200, 000.00 paid within one week as from the date Party B provide all formal research report 
 The fund and remuneration shall be remitted to the account designated by Party B, and Party B shall provide invoices in accordance with Party A’s requirements. 
 In case SFDA determine at its discretion that relevant reports shall be modified and additional experiments shall be carried out, Party B shall complete relevant work in accordance with SFDA’s requirements as
soon as possible, and Party A need not make additional payments therefor. 
 5. Ownership of Equipments, Devices, Materials Bought with Research and
Development Fund 
 Null 
 6. Term, Site and Performance
Mode 
 This Agreement shall be performed from November 10th, 2006 to January 10th, 2008 at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. 
 7. Confidentiality 
 Party B shall keep all samples, background materials provided by Party A and experimental data generated from the research confidential, and shall not disclose relevant
information to the public and have them published without the consent of Party A. 
 8. Technical Assistance and Direction 
 Null 
 9. Risk 
 Any and all losses arising from the failure of all or part of the research and development due to force majeure occurring during the term of this Agreement shall be born
by Party A. 

 10. Ownership and Share of Technical Achievements 
 10.1 Patent application right shall belong to Party A. 
 10.2 The right to profit and transfer on the know-how shall belong
to Party A. 
 11. Examination and Acceptance 
 The
technical achievements generated from the project shall satisfy technological indexes and parameters specified in Article 2. Under the condition that Endostar is effective on those tumor models, the preclinical pharmacodynamic research report on
Endostar’s new indications provided by Party B shall be approved by SFDA and Party B shall be responsible to answer relevant questions about the preclinical pharmacodynamic research on Endostar’s new indications when Party A carry out IND
declarations. 
 12. Damages and Liquidation 
 In case this Agreement is violated, the default party shall undertake relevant default liabilities in accordance with Contract Law of People’s Republic of China. 
  

	12.1	If Party A violates Article 1, Article 4, Article 9 of this Agreement, Party B shall be entitled to 5-10% of the research and development fund as the penalty.

  

	12.2	If Party B violates Article 1, Article 2, Article 3, Article 6, Article 7, Article 10, Article 11 of this Agreement, Party B shall be entitled to reduce 5-10% of the research and
development fund as the penalty. 

  

	12.3	Others: 

  

	12.3.1	Party B shall not undertake any responsibilities if the pharmacodynamic effects of samples provided by Party A does not meet IND application requirements. 

 

	12.3.2	In case this Agreement shall be terminated due to objective reason, parties hereto shall negotiate on the termination thereof. Notwithstanding that, Party B shall be entitled to
research and development fund in accordance with the competition ratio of relevant experiments. 

 13. Dispute Settlement 
 If there is any dispute arising from the performance of this Agreement, parties hereto shall first attempt to resolve such dispute through negotiation or request
intermediation. If the dispute could not be resolved through negotiation or intermediation, parties hereto agree to submit the dispute to Shanghai Arbitration Commission for arbitration. 
 14. Definition 
 Null 
 15. Miscellaneous 
 15.1 This Agreement shall be made in 6 copies, parties hereto shall each have 2 copies, and the Contract Registration
Authority and Shanghai Technology Market Management Office each shall have one copy. 
 15.2 The copies of this Agreement respectively held by Party A and
Party B shall have the same legal force and effect. 
 15.3 Any matter unmentioned in this Agreement shall be otherwise negotiated by parties hereto.

 Party A: Jiangsu Simcere Pharmaceutical R&D Co Ltd 
 Legal Representative: 
 Duly Authorized Representative: 
 Project Manager 
 Address: 
 Telephone Number 
 Bank Account 
 Party B: Shanghai Institute of Materia Medica, Chinese Academy of Sciences 
 Legal Representative: 
 Duly Authorized Represnetative: 
 Project Manager 
 Address: 
 Telephone Number

 Bank Account

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]